» Articles » PMID: 34202364

Cystic Fibrosis Human Organs-on-a-Chip

Overview
Publisher MDPI
Date 2021 Jul 2
PMID 34202364
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene: the gene product responsible for transporting chloride and bicarbonate ions through the apical membrane of most epithelial cells. Major clinical features of CF include respiratory failure, pancreatic exocrine insufficiency, and intestinal disease. Many CF animal models have been generated, but some models fail to fully capture the phenotypic manifestations of human CF disease. Other models that better capture the key characteristics of the human CF phenotype are cost prohibitive or require special care to maintain. Important differences have been reported between the pathophysiology seen in human CF patients and in animal models. These limitations present significant limitations to translational research. This review outlines the study of CF using patient-derived organs-on-a-chip to overcome some of these limitations. Recently developed microfluidic-based organs-on-a-chip provide a human experimental model that allows researchers to manipulate environmental factors and mimic in vivo conditions. These chips may be scaled to support pharmaceutical studies and may also be used to study organ systems and human disease. The use of these chips in CF discovery science enables researchers to avoid the barriers inherent in animal models and promote the advancement of personalized medicine.

Citing Articles

Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.

Alqasmi M J Clin Med. 2024; 13(21).

PMID: 39518670 PMC: 11547045. DOI: 10.3390/jcm13216530.


Human organoids-on-chips for biomedical research and applications.

Wang H, Ning X, Zhao F, Zhao H, Li D Theranostics. 2024; 14(2):788-818.

PMID: 38169573 PMC: 10758054. DOI: 10.7150/thno.90492.


Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities.

Hubert L, Barton T, Leighton H, Richards B Microbiology (Reading). 2023; 169(7).

PMID: 37428539 PMC: 10433426. DOI: 10.1099/mic.0.001361.


Recent Developments in Inertial and Centrifugal Microfluidic Systems along with the Involved Forces for Cancer Cell Separation: A Review.

Farahinia A, Zhang W, Badea I Sensors (Basel). 2023; 23(11).

PMID: 37300027 PMC: 10256097. DOI: 10.3390/s23115300.


Easy-to-Build and Reusable Microfluidic Device for the Dynamic Culture of Human Bronchial Cystic Fibrosis Epithelia.

Mazio C, Scognamiglio L, Passariello R, Panzetta V, Casale C, Urciuolo F ACS Biomater Sci Eng. 2023; 9(5):2780-2792.

PMID: 37019688 PMC: 10170479. DOI: 10.1021/acsbiomaterials.2c01460.


References
1.
Sun X, Sui H, Fisher J, Yan Z, Liu X, Cho H . Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest. 2010; 120(9):3149-60. PMC: 2929732. DOI: 10.1172/JCI43052. View

2.
da Silva Xavier G . The Cells of the Islets of Langerhans. J Clin Med. 2018; 7(3). PMC: 5867580. DOI: 10.3390/jcm7030054. View

3.
Wilschanski M, Novak I . The cystic fibrosis of exocrine pancreas. Cold Spring Harb Perspect Med. 2013; 3(5):a009746. PMC: 3633181. DOI: 10.1101/cshperspect.a009746. View

4.
Fanen P, Wohlhuter-Haddad A, Hinzpeter A . Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int J Biochem Cell Biol. 2014; 52:94-102. DOI: 10.1016/j.biocel.2014.02.023. View

5.
Cook D, Rector M, Bouzek D, Michalski A, Gansemer N, Reznikov L . Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility. Am J Respir Crit Care Med. 2015; 193(4):417-26. PMC: 4803085. DOI: 10.1164/rccm.201508-1562OC. View